alphaveNATCOPHARM₹818.80

NATCO Pharma Ltd.

Annual Quarterly₹ CrorePeersDRREDDY ZYDUSLIFE SUNPHARMA LALPATHLAB NEULANDLAB NH SAILIFE COHANCEMcap ₹14,657 Cr

View

In ₹ Crore except Per Share 12 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,031.4	758.6	1,068.3	1,362.6	1,371.1	474.8	1,221.0	1,328.9	1,363.0	647.3	739.1	735.2
Other Income	29.4	37.0	42.0	48.1	63.8	176.3	66.3	61.7	100.0	58.1	77.8	59.2
Total Income	1,060.8	795.6	1,110.3	1,410.7	1,434.9	651.1	1,287.3	1,390.6	1,463.0	705.4	816.9	794.4
Expenses
+ Cost of Materials Consumed	166.5	92.2	127.6	151.3	143.2	72.7	169.0	180.6	174.9	135.2	102.8	157.8
+ Purchases of Stock-in-Trade	41.0	36.7	31.1	32.5	53.7	39.1	40.8	37.3	72.6	55.8	37.5	27.8
+ Changes in Inventories	8.3	33.3	-16.1	-3.6	-19.3	-29.0	39.4	15.1	-77.8	-57.9	14.4	-38.1
+ Employee Benefit Expense	122.4	121.9	142.5	142.0	151.5	141.6	159.4	169.0	200.3	159.4	158.5	179.3
+ Finance Costs	4.2	4.6	6.2	5.2	4.1	4.4	10.2	3.2	13.1	9.5	10.9	13.0
+ Depreciation & Amortisation	43.6	44.2	55.5	44.1	45.8	47.0	98.3	57.6	52.4	46.2	50.4	47.1
+ Other Expenses	235.2	206.4	285.9	235.6	237.7	211.6	264.3	355.9	413.8	196.1	298.3	221.9
Total Expenses	621.2	539.3	632.7	607.1	616.7	487.4	781.4	818.7	849.3	544.3	672.8	608.8
EBITDA	458.0	268.1	497.3	804.8	804.3	38.8	548.1	571.0	579.2	158.7	127.6	186.5
EBIT	414.4	223.9	441.8	760.7	758.5	-8.2	449.8	513.4	526.8	112.5	77.2	139.4
Profit
PBT before Exceptional Items	439.6	256.3	477.6	803.6	818.2	163.7	505.9	571.9	613.7	161.1	144.1	185.6
Pretax Income	439.6	256.3	477.6	803.6	818.2	163.7	505.9	571.9	613.7	161.1	144.1	185.6
+ Current Tax	81.9	52.2	90.3	143.6	154.1	33.5	106.4	115.7	140.4	31.3	16.1	48.8
+ Deferred Tax	-11.3	-8.6	1.0	-8.5	-12.4	-2.2	-6.5	-24.1	-44.6	-10.6	-105.3	14.6
Tax Expense	70.6	43.6	91.3	135.1	141.7	31.3	99.9	91.6	95.8	20.7	-89.2	63.4
+ Share of Associates & JVs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.9	35.7	84.3
Net Income	369.0	212.7	386.3	668.5	676.5	132.4	406.0	480.3	517.9	151.3	269.0	206.5
+ Net Income — Continuing Ops	369.0	212.7	386.3	668.5	676.5	132.4	406.0	480.3	517.9	140.4	233.3	122.2
+ Other Comprehensive Income	-4.8	17.9	-12.5	-14.4	19.2	-10.6	-18.2	39.3	40.4	124.5	83.2	111.0
Total Comprehensive Income	364.2	230.6	373.8	654.1	695.7	121.8	387.8	519.6	558.3	275.8	352.2	317.5
Net Income to Common	369.0	212.7	386.3	668.5	677.3	133.0	406.6	480.7	518.4	151.5	267.9	206.5
Minority Interest	0.0	0.0	0.0	0.0	-0.8	-0.6	-0.6	-0.4	-0.5	-0.2	1.1	0.0
Per Share
Basic EPS	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Diluted EPS	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-18.2	39.3	40.4	124.5	83.2	111.0
+ Items NOT to be Reclassified to P&L	2.5	2.8	-1.8	2.2	4.3	15.4	-25.3	4.6	14.8	7.1	13.8	8.9
+ Tax on Items NOT to be Reclassified — alt tag	0.3	0.3	0.0	0.0	-14.9	0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-7.0	15.4	-10.7	-16.6	0.0	-26.0	7.1	34.7	25.6	117.4	69.4	102.1
Comprehensive Income — Owners of Parent	364.2	230.6	373.8	654.1	696.5	122.4	388.4	520.0	558.8	276.0	351.1	317.5
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	0.0	-0.8	-0.6	-0.6	-0.4	-0.5	-0.2	1.1	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Diluted EPS — Continuing Operations	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	815.6	596.4	925.7	1,182.4	1,193.5	392.0	971.8	1,095.9	1,193.3	514.2	584.4	587.7
Gross Margin %	79.08	78.62	86.65	86.78	87.05	82.56	79.59	82.47	87.55	79.44	79.07	79.94
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	439.6	256.3	477.6	803.6	818.2	163.7	505.9	571.9	613.7	161.1	144.1	185.6
Net Income Adj (tax-effected)	369.0	212.7	386.3	668.5	676.5	132.4	406.0	480.3	517.9	151.3	269.0	206.5
EPS Adj	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.